Why reauthorization of the Rare Pediatric Disease Priority Review Voucher (PPRV) Program is vital
The Food and Drug Administration’s (FDA) Rare Pediatric Disease Priority Review Voucher (PPRV) Program was top of mind during BIO’s March Patient Advocacy Coffee […]